PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Icosapent - Lipid modification

PAD Profile : Icosapent - Lipid modification

Keywords :
raised triglycerides, hypertriglyceridaemia
Brand Names Include :
Vazkepa

Traffic Light Status

Status 1 of 1.

Status :
Green
Important
Formulations :
  • Capsules
Important Information :
With statin therapy in patients with raised triglycerides
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
05 October 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve Icosapent ethyl with statin therapy as a treatment option for reducing the risk of cardiovascular events in people with raised triglycerides in line with NICE TA805.
Icosapent ethyl for this indication will be considered as GREEN on the traffic light status.
The committee noted an increased risk of atrial fibrillation or fluttter - prescribers should consider advice given in the Summary of Product Charcteristics available at https://www.medicines.org.uk/emc/product/12964

Associated BNF Codes

02. Cardiovascular System
02.12.00. Lipid-regulating drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More